Literature DB >> 27747478

Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications.

Stefan Stefanovic1, Markus Wallwiener2, Uros Karic3, Christoph Domschke1, Luka Katic3, Florin-Andrei Taran4, Aleksandra Pesic3, Andreas Hartkopf4, Peyman Hadji5, Martin Teufel6, Florian Schuetz1, Christof Sohn1, Peter Fasching7, Andreas Schneeweiss1,8, Sara Brucker9.   

Abstract

PURPOSE: The capture of adequate treatment outcomes and quality of life (QOL) of advanced breast cancer patients in clinical routine represents a great challenge. Patient-reported outcomes (PROs) are data elements directly reported by patients about experiences with care, including symptoms, functional status, or quality of life. There is growing interest in the medical community for the evaluation and implementation of PROs of adverse events (PRO-AEs). Recent interest in PROs in health care has evolved in the context of patient centeredness. Our primary objective was to identify trials that had implemented PRO-AEs in the breast cancer treatment setting, thereby demonstrating its feasibility. We aimed to identify published studies that used patient reports to assess AEs during and after breast cancer treatment, to identify clinician underreported and modifiable AEs that are important to patients, and to analyze the feasibility and usefulness of PRO instrument implementation in everyday oncological practice with special attention given to electronic-based PRO instruments.
METHODS: We conducted a systematic search of PubMed for studies that used PRO instruments to assess AEs of breast cancer treatment in the metastatic and adjuvant settings. Two authors independently reviewed the search results and decided which studies fully met the predefined inclusion criteria.
RESULTS: The search yielded 606 publications. The two reviewers found that 9 studies met the inclusion criteria. Three AEs were identified as important to patients but inadequately reported by health care providers, namely hot flushes, vaginal dryness, and weight gain.
CONCLUSIONS: PROs and PRO-AEs are the consequence of contemporary concepts of patient-centered medicine and the growing feasibility, utility, and implications of collecting data using modern technology. Furthermore, the willingness of patients to utilize innovative applications for their own health has been increasing in parallel to the enhanced impact of the World Wide Web. Especially, the coverage of the metastatic situation promises numerous findings on the structure and quality of health care, enabling implementation of individually tailored interventions. Remote electronic self-reporting (i.e., home reporting) is feasible and is associated with high compliance levels.

Entities:  

Keywords:  Adjuvant; Adverse events; Breast cancer; Metastatic; Patient-reported outcome

Mesh:

Year:  2016        PMID: 27747478     DOI: 10.1007/s00520-016-3437-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  53 in total

Review 1.  The role of patient-reported outcomes in evaluating the quality of oncology care.

Authors:  Cheryl R Dennison
Journal:  Am J Manag Care       Date:  2002-12       Impact factor: 2.229

2.  Evaluating outcome criteria used in methadone maintenance programs.

Authors:  M Cohen; A Howard; D F Klein; K Newfield
Journal:  Int J Addict       Date:  1976

3.  Body mass index and risk of cardiovascular disease, cancer and all-cause mortality.

Authors:  Peter T Katzmarzyk; Bruce A Reeder; Susan Elliott; Michel R Joffres; Punam Pahwa; Kim D Raine; Susan A Kirkland; Gilles Paradis
Journal:  Can J Public Health       Date:  2012 Mar-Apr

4.  Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.

Authors:  Chantal Quinten; John Maringwa; Carolyn C Gotay; Francesca Martinelli; Corneel Coens; Bryce B Reeve; Henning Flechtner; Eva Greimel; Madeleine King; David Osoba; Charles Cleeland; Jolie Ringash; Joseph Schmucker-Von Koch; Martin J B Taphoorn; Joachim Weis; Andrew Bottomley
Journal:  J Natl Cancer Inst       Date:  2011-12-07       Impact factor: 13.506

5.  Prevalence of breast cancer treatment sequelae over 6 years of follow-up: the Pulling Through Study.

Authors:  Kathryn H Schmitz; Rebecca M Speck; Sheree A Rye; Tracey DiSipio; Sandra C Hayes
Journal:  Cancer       Date:  2012-04-15       Impact factor: 6.860

6.  Locating pain in breast cancer survivors experiencing dyspareunia: a randomized controlled trial.

Authors:  Martha F Goetsch; Jeong Y Lim; Aaron B Caughey
Journal:  Obstet Gynecol       Date:  2014-06       Impact factor: 7.661

7.  Endocrine symptom assessment in women with breast cancer: what a simple "yes" means.

Authors:  K Ribi; J Bernhard; K Rufibach; B Thürlimann; R von Moos; T Ruhstaller; A Glaus; C Böhme
Journal:  Support Care Cancer       Date:  2007-05-26       Impact factor: 3.603

8.  Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study.

Authors:  Thomas Ruhstaller; Roger von Moos; Kaspar Rufibach; Karin Ribi; Agnes Glaus; Bruno Spaeti; Dieter Koeberle; Urs Mueller; Markus Hoefliger; Dagmar Hess; Christel Boehme; Beat Thuerlimann
Journal:  Oncology       Date:  2009-01-22       Impact factor: 2.935

Review 9.  New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment.

Authors:  Ethan Basch
Journal:  Annu Rev Med       Date:  2013-11-20       Impact factor: 13.739

10.  Body fat percentage, body mass index and waist-to-hip ratio as predictors of mortality and cardiovascular disease.

Authors:  Phyo Kyaw Myint; Chun Shing Kwok; Robert N Luben; Nicholas J Wareham; Kay-Tee Khaw
Journal:  Heart       Date:  2014-10       Impact factor: 5.994

View more
  5 in total

1.  Estimation of Symptom Severity During Chemotherapy From Passively Sensed Data: Exploratory Study.

Authors:  Carissa A Low; Anind K Dey; Denzil Ferreira; Thomas Kamarck; Weijing Sun; Sangwon Bae; Afsaneh Doryab
Journal:  J Med Internet Res       Date:  2017-12-19       Impact factor: 5.428

2.  Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.

Authors:  Joachim Graf; Sara Y Brucker; Markus Wallwiener; Lina Matthies; Elisabeth Simoes; Lucia Keilmann; Andreas D Hartkopf; Alexander N Sokolov; Christina B Walter; Nina Sickenberger; Stephanie Wallwiener; Manuel Feisst; Paul Gass; Peter A Fasching; Michael P Lux; Diethelm Wallwiener; Florin-Andrei Taran; Joachim Rom; Andreas Schneeweiss
Journal:  J Med Internet Res       Date:  2017-09-14       Impact factor: 5.428

3.  Mobile App for Symptom Management and Associated Quality of Life During Systemic Treatment in Early Stage Breast Cancer: Nonrandomized Controlled Prospective Cohort Study.

Authors:  Nina Ružić Gorenjec; Cvetka Grašič Kuhar; Tjaša Gortnar Cepeda; Timotej Kovač; Matjaž Kukar
Journal:  JMIR Mhealth Uhealth       Date:  2020-08-04       Impact factor: 4.773

4.  Barriers to Electronic Patient-Reported Outcome Measurement Among Patients with Cancer and Limited English Proficiency.

Authors:  Elena Garcia Farina; Jessi Rowell; Anna Revette; Ellana K Haakenstad; Jessica L F Cleveland; Rachel Allende; Michael Hassett; Deborah Schrag; Nadine J McCleary
Journal:  JAMA Netw Open       Date:  2022-07-01

5.  An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study.

Authors:  Lina Maria Matthies; Florin-Andrei Taran; Joachim Graf; Markus Wallwiener; Lucia Keilmann; Andreas Schneeweiss; Elisabeth Simoes; Andreas D Hartkopf; Alexander N Sokolov; Christina B Walter; Nina Sickenberger; Stephanie Wallwiener; Manuel Feisst; Paul Gass; Michael P Lux; Florian Schuetz; Peter A Fasching; Christof Sohn; Sara Y Brucker
Journal:  J Med Internet Res       Date:  2019-01-22       Impact factor: 5.428

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.